What is Immunis.AI?
Immunis.AI operates at the intersection of advanced computational intelligence and immunological science. By providing a suite of sophisticated tools, the company enables healthcare professionals and research organizations to streamline their data analysis and treatment development processes. Their platform is engineered to address the critical need for precision in medical research, effectively bridging the gap between raw biological data and actionable clinical insights. As the healthcare sector increasingly pivots toward data-centric methodologies, Immunis.AI is positioned as a pivotal infrastructure provider for institutions aiming to optimize patient outcomes through technological innovation.
How much funding has Immunis.AI raised?
Immunis.AI has raised a total of $40M across 1 funding round:
Unspecified
$40M
Unspecified (2021): $40M, investors not publicly disclosed
Key Investors in Immunis.AI
Undisclosed Investor
Undisclosed investor participating in the funding round.
Undisclosed Investor
Undisclosed investor participating in the funding round.
Undisclosed Investor
Undisclosed investor participating in the funding round.
What's next for Immunis.AI?
With this major enterprise-level funding, Immunis.AI is expected to accelerate its product development roadmap and expand its footprint in the global healthcare market. The strategic allocation of this capital will likely focus on scaling their proprietary AI algorithms and enhancing the interoperability of their research tools with existing clinical workflows. As the company transitions into its next phase of growth, the focus will remain on establishing long-term partnerships with major research institutions and pharmaceutical entities, thereby solidifying its role as a cornerstone of modern, AI-driven immunological research and therapeutic development.
See full Immunis.AI company page
